You are here: Home » Opinion » Financial X-Ray
Business Standard

Street picks Aurobindo Pharma ahead of larger peers on injectibles business

25 approved ANDAs, 115 pending ANDAs likely to be huge growth boosters

Ujjval Jauhari 

Aurobindo Pharma is among the few companies that are confident about growth in the US. It believes launches and higher volume will drive growth there, despite pricing pressure in the base business. The management confidence, in a sector jittery about US prospects, helped the stock rebound from its May 25 low and gain 10.5 per cent since then.  Its March quarter performance, like peers, was impacted by price erosion in the US. The US formulation sales, contributes 45 per cent to overall revenue, are expected to grow only 1.4 per cent over a year due to pricing pressure in oral ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
RECOMMENDED FOR YOU

Street picks Aurobindo Pharma ahead of larger peers on injectibles business

25 approved ANDAs, 115 pending ANDAs likely to be huge growth boosters

Aurobindo Pharma is among the few companies which are confident about growth in the US market. The company believes that new launches and higher volume will drive growth in US, despite pricing pressure witnessed in the US base business. Management confidence in a sector jittery about US prospects helped the stock rebound from May 25 lows and gain 10.5 per cent since then. The company's March quarter performance like its peers was impacted by price erosion in the US market. The US formulation sales which contributes about 45 per cent to overall revenues is expected to grow just 1.4 per cent y-o-y due to pricing pressure in oral solids which is expected to continue in FY18. However pending launches, company's range of injectable and other complex portfolio is expected to drive revenue and net profit growth. Since April 2015, while the company has received 110 final ANDA approvals, more than 25 are yet to be launched and these together with 115 pending ANDAs should provide strong growth . Aurobindo Pharma is among the few companies that are confident about growth in the US. It believes launches and higher volume will drive growth there, despite pricing pressure in the base business. The management confidence, in a sector jittery about US prospects, helped the stock rebound from its May 25 low and gain 10.5 per cent since then.  Its March quarter performance, like peers, was impacted by price erosion in the US. The US formulation sales, contributes 45 per cent to overall revenue, are expected to grow only 1.4 per cent over a year due to pricing pressure in oral ... image
Business Standard
177 22

Street picks Aurobindo Pharma ahead of larger peers on injectibles business

25 approved ANDAs, 115 pending ANDAs likely to be huge growth boosters

Aurobindo Pharma is among the few companies that are confident about growth in the US. It believes launches and higher volume will drive growth there, despite pricing pressure in the base business. The management confidence, in a sector jittery about US prospects, helped the stock rebound from its May 25 low and gain 10.5 per cent since then.  Its March quarter performance, like peers, was impacted by price erosion in the US. The US formulation sales, contributes 45 per cent to overall revenue, are expected to grow only 1.4 per cent over a year due to pricing pressure in oral ...

image
Business Standard
177 22